Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.

Plus deals involving AstraZeneca/Allorion, Concentra/Theseus, Janssen/MeiraGTx, Lilly/Fauna and more.

Kite’s senior director and head of medical affairs, Intercontinental Region, Tony Li, talks to Scrip about the company's efforts to enable timely and broad access to Yescarta in Singapore, where wider cancer drug procurement prices have declined following policy changes. A patient is already on course to being prepped for Kite's CAR-T cell therapy.

Gilead aims to launch its key oncology product Trodelvy by 2024 in Japan while building a dedicated business unit for oncology in the firm’s Japanese office. The firm has expanded its exclusive rights for oncology products in APAC.